2026 Q3 Portfolio Activity
In 2026 Q3, EcoR1 Capital, LLC maintained a portfolio of 43 distinct positions. The most significant new addition was BRISTOL-MYERS SQUIBB CO, now representing 9.70% of the total fund value. They heavily accumulated shares in CG ONCOLOGY INC, increasing the position by 233.4%. Conversely, EcoR1 Capital, LLC completely exited their position in CG ONCOLOGY INC.
Position History
hover any row below to update
Loading…
Total Positions
43
Quarter
2026 Q3
Top Holding
ZYME (27.0%)
Top 10 Concentration
83.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-43 of 43
EcoR1 Capital, LLC Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ZYME
ZYMEWORKS INC
|
Healthcare | 27.01% | 29.19% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
22,970,388 | $608,485,578 |
$10.13
nan%
|
2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
ANAB
ANAPTYSBIO INC
|
Healthcare | 17.58% | 25.86% |
#2
Prev: #2
|
6.5 |
—
|
no change | no change |
P
S
|
7,880,094 | $396,053,524 |
$13.09
nan%
|
2019 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
BMY
CALL
BRISTOL-MYERS S...
|
CALL Option | 9.70% | — |
#3
Prev: #—
|
8.4 |
—
|
3,500,000 | — |
NEW
|
3,500,000 | $218,400,000 |
$61.65
+2.1%
|
2016 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 5.89% | 5.16% |
#4
Prev: #4
|
5.4 |
—
|
377,592 | 25.3% |
P
S
|
1,871,892 | $132,698,424 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ETON
ETON PHARMACEUT...
|
Healthcare | 5.65% | 3.82% |
#5
Prev: #5
|
4.8 |
—
|
298,982 | 13.8% |
P
S
|
2,470,920 | $127,227,671 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TRAX
FIRST TRACKS BI...
|
Healthcare | 4.99% | 3.11% |
#6
2
Prev: #8
|
3.0 |
—
|
no change | no change |
P
S
|
3,174,519 | $112,504,953 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AKTS
AKTIS ONCOLOGY ...
|
Healthcare | 4.17% | 7.56% |
#7
4
Prev: #3
|
2.7 |
—
|
no change | no change |
P
S
|
4,824,469 | $93,932,411 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CRSP
CRISPR THERAPEU...
|
Healthcare | 3.41% | 3.68% |
#8
2
Prev: #6
|
2.4 |
—
|
no change | no change |
P
S
|
1,389,276 | $76,854,748 | 2018 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 2.53% | — |
#9
Prev: #—
|
4.5 |
—
|
2,232,000 | — |
NEW
|
2,232,000 | $56,982,960 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GLPG
LAKEFRONT BIOTH...
|
Healthcare | 2.19% | 2.43% |
#10
1
Prev: #9
|
1.9 |
—
|
no change | no change |
P
S
|
1,667,119 | $49,430,078 | 2015 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ERAS
ERASCA INC
|
Healthcare | 1.92% | 0.29% |
#11
16
Prev: #27
|
3.8 |
—
|
2,620,000 | 793.9% |
P
S
|
2,950,000 | $43,247,000 | 2021 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ORIC
ORIC PHARMACEUT...
|
Healthcare | 1.81% | 3.54% |
#12
5
Prev: #7
|
0.7 |
—
|
-3,700,000 | -55.0% |
P
S
|
3,028,116 | $40,788,723 | 2020 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NGNE
NEUROGENE INC
|
Healthcare | 1.57% | 1.94% |
#13
3
Prev: #10
|
1.6 |
—
|
no change | no change |
P
S
|
1,271,342 | $35,368,734 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
ATTOVIA THERAPE...
|
|
Unknown | 1.54% | — |
#14
Prev: #—
|
4.1 |
—
|
2,024,010 | — |
NEW
|
2,024,010 | $34,691,531 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
FULC
FULCRUM THERAPE...
|
Healthcare | 1.12% | 1.17% |
#15
2
Prev: #13
|
0.9 |
—
|
253,919 | 3.9% |
P
S
|
6,803,785 | $25,174,005 | 2020 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ADRX
ADARX PHARMACEU...
|
Healthcare | 1.02% | — |
#16
Prev: #—
|
3.9 |
—
|
1,150,000 | — |
NEW
|
1,150,000 | $22,931,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
STOK
STOKE THERAPEUT...
|
Healthcare | 0.96% | 1.17% |
#17
5
Prev: #12
|
2.4 |
—
|
100,000 | 13.6% |
P
S
|
835,000 | $21,710,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ZBIO
ZENAS BIOPHARMA...
|
Healthcare | 0.95% | 0.97% |
#18
1
Prev: #17
|
1.4 |
—
|
no change | no change |
P
S
|
789,500 | $21,292,815 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ETRA
ELECTRA THERAPE...
|
Healthcare | 0.85% | — |
#19
Prev: #—
|
3.8 |
—
|
1,700,000 | — |
NEW
|
1,700,000 | $19,125,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ATRA
ATARA BIOTHERAP...
|
Healthcare | 0.59% | 0.87% |
#20
2
Prev: #18
|
1.2 |
—
|
no change | no change |
P
S
|
1,552,000 | $13,192,000 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CAPR
CAPRICOR THERAP...
|
Healthcare | 0.58% | — |
#21
Prev: #—
|
3.7 |
—
|
1,376,580 | — |
NEW
|
1,376,580 | $13,036,213 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
XNCR
XENCOR INC
|
Healthcare | 0.55% | — |
#22
Prev: #—
|
3.7 |
—
|
500,000 | — |
NEW
|
500,000 | $12,475,000 | 2016 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ODTX
ODYSSEY THERAPE...
|
Healthcare | 0.55% | 0.51% |
#23
2
Prev: #21
|
1.2 |
—
|
no change | no change |
P
S
|
555,555 | $12,344,432 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AURA
AURA BIOSCIENCE...
|
Healthcare | 0.46% | 0.58% |
#24
4
Prev: #20
|
1.2 |
—
|
no change | no change |
P
S
|
1,666,667 | $10,466,669 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 0.39% | 0.32% |
#25
1
Prev: #26
|
2.7 |
—
|
105,000 | 38.9% |
P
S
|
375,000 | $8,891,250 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BRVE
BRAVEHEART BIO ...
|
Healthcare | 0.37% | — |
#26
Prev: #—
|
3.6 |
—
|
416,700 | — |
NEW
|
416,700 | $8,417,340 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 0.33% | 0.40% |
#27
4
Prev: #23
|
1.1 |
—
|
no change | no change |
P
S
|
235,000 | $7,454,200 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EIKN
EIKON THERAPEUT...
|
Healthcare | 0.31% | 0.46% |
#28
6
Prev: #22
|
2.1 |
—
|
123,028 | 16.8% |
P
S
|
855,634 | $6,879,297 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ELOX
ELOXX PHARMACEU...
|
Healthcare | 0.27% | 0.27% |
#29
1
Prev: #28
|
1.1 |
—
|
no change | no change |
P
S
|
400,000 | $6,124,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AARD
AARDVARK THERAP...
|
Healthcare | 0.17% | 0.11% |
#30
1
Prev: #29
|
3.1 |
—
|
323,834 | 81.7% |
P
S
|
720,028 | $3,794,548 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 0.16% | 1.05% |
#31
16
Prev: #15
|
0.1 |
—
|
-1,933,519 | -68.5% |
P
S
|
889,607 | $3,647,389 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
TCGX ACQUISITIO...
|
|
Unknown | 0.14% | — |
#32
Prev: #—
|
3.6 |
—
|
250,000 | — |
NEW
|
250,000 | $3,127,500 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
ZURA
ZURA BIO LTD
|
Healthcare | 0.13% | 0.34% |
#33
9
Prev: #24
|
0.1 |
—
|
-500,000 | -42.4% |
P
S
|
679,715 | $2,827,614 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
HELIX ACQUISITI...
|
|
Unknown | 0.09% | 0.10% |
#34
4
Prev: #30
|
1.0 |
—
|
no change | no change |
P
S
|
200,000 | $2,124,000 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
CTNM
CONTINEUM THERA...
|
Healthcare | 0.04% | — |
#35
Prev: #—
|
3.5 |
—
|
64,303 | — |
NEW
|
64,303 | $862,946 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CGON
CALL
CG ONCOLOGY INC
|
CALL Option | 0.00% | 1.94% |
#36
25
Prev: #11
|
0.0 |
—
|
-561,400 | -100.0% |
P
S
|
100 | $7,089 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AARD
CALL
AARDVARK THERAP...
|
CALL Option | 0.00% | 0.00% |
Sold All 😨
(Was: #33) |
0.0 |
—
|
-14,700 | -100.0% |
CLOSED
|
— | $— | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SRZNW
SURROZEN INC
|
Unknown | 0.00% | 0.01% |
Sold All 😨
(Was: #32) |
0.0 |
—
|
-4,444 | -100.0% |
CLOSED
|
— | $— | 2021 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MREO
MEREO BIOPHARMA...
|
Healthcare | 0.00% | 0.02% |
Sold All 😨
(Was: #31) |
0.0 |
—
|
-1,000,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 0.00% | 0.33% |
Sold All 😨
(Was: #25) |
0.0 |
—
|
-625,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 0.00% | 0.63% |
Sold All 😨
(Was: #19) |
0.0 |
—
|
-697,948 | -100.0% |
CLOSED
|
— | $— | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 0.00% | 1.04% |
Sold All 😨
(Was: #16) |
0.0 |
—
|
-388,500 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LEGN
LEGEND BIOTECH ...
|
Healthcare | 0.00% | 1.12% |
Sold All 😨
(Was: #14) |
0.0 |
—
|
-800,000 | -100.0% |
CLOSED
|
— | $— | 2021 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-43 of 43 holdings